YOLFTbeta
Addex Therapeutics Ltd

Addex Therapeutics Ltd

ADXN · NASDAQ · Healthcare / Biotechnology

4.06USD-1.23 (-23.25%)

Price History

Full chart

Market Stats

Previous Close5.29
Open4.75
Day Range3.75 – 5.00
52-Week Range3.10 – 11.97
Volume548.50K
Market Cap4.38M
P/E (TTM)0.00
Forward P/E0.00
EPS-8.80
Dividend Yield0.00%
Beta1.96
50-Day Avg4.80
200-Day Avg6.47

About

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Timothy Mark Dyer
  • Employees3
  • HeadquartersChemin des Mines, 9, Geneva, Switzerland, 1202, USA
  • Websitehttps://www.addextherapeutics.com

Leadership

  • Mr. Timothy Mark DyerCo-Founder, CEO & Director · b. 1968
  • Dr. Roger G. Mills M.D.Chief Medical Officer & Director · b. 1957
  • Mr. Lénaic TeyssédouHead of Finance · b. 1985
  • Dr. Mikhail Kalinichev Ph.D.Head of Translational Science · b. 1967

Financials

Income Statement

Currency: CHF2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.74M486.93K26.81M4.09M1.98M2.82M121.09K91.76K85.40K40.30K17.33K499.89K6.04M2.76M3.61M2.92M1.42M1.61M404.10K29.97K
Growth (%)--89.72%+5405.28%-84.74%-51.71%+42.94%-95.71%-24.22%-6.93%-52.81%-57.00%+2784.73%+1109.03%-54.29%+30.77%-19.28%-51.22%+13.39%-74.95%-92.58%
Cost of Revenue--156.03K--31.16M27.99M1.27M91.76K85.40K40.30K17.33K29.76K144.17K230.10K10.37M12.82M14.62M6.94M854.30K10.20K
Gross Profit4.74M642.96K26.81M4.09M-29.19M-25.16M-1.15M-030.04K-407.59K470.13K5.90M2.53M3.61M2.92M1.42M1.61M404.10K29.97K
Gross Margin100.00%132.04%100.00%100.00%-1477.75%-891.19%-948.14%-0.00%74.55%-2352.05%94.05%97.61%91.67%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense25.64M38.26M51.68M47.15M4.41M5.81M25.86M-1.80M3.90M2.72M3.71M7.32M17.14M15.86M18.42M11.96M3.86M3.16M2.84M
Operating Income-20.90M-37.62M-24.87M-43.05M-33.60M-30.97M-27.01M-14.46M-1.80M-3.87M-3.13M-3.24M-1.42M-14.60M-12.24M-15.51M-10.54M-2.24M-2.76M-2.81M
Operating Margin-441.03%-7726.28%-92.78%-1052.47%-1700.93%-1097.02%-22306.25%-15756.97%-2103.69%-9597.64%-18059.88%-647.15%-23.57%-528.59%-338.88%-531.70%-741.04%-139.06%-681.82%-9390.76%
EBITDA-17.99M-33.26M-19.55M-39.86M-30.56M-28.05M-24.87M-13.79M-1.71M-2.61M-3.12M-3.22M-1.51M-14.32M-12.41M-14.94M-10.45M-2.19M-4.65M-6.83M
EBITDA Margin-379.66%-6830.55%-72.92%-974.30%-1547.10%-993.33%-20542.67%-15026.90%-1998.26%-6488.51%-17979.05%-644.10%-24.94%-518.25%-343.51%-512.34%-734.86%-135.80%-1149.63%-22793.59%
Net Income-20.54M-35.09M-22.07M-42.69M-33.65M-31.14M-26.61M-14.46M-1.77M-4.20M-3.15M-3.28M-1.64M-14.78M-12.86M-15.35M-20.80M-10.56M7.06M-6.73M
Net Income Margin-433.53%-7205.50%-82.32%-1043.62%-1703.33%-1102.95%-21976.79%-15760.49%-2078.19%-10432.03%-18174.08%-656.22%-27.21%-534.98%-355.92%-526.42%-1462.57%-654.47%1746.04%-22448.44%
R&D9.77M12.21M44.19M39.96M31.16M4.76M4.76M2.22M258.06K761.22K819.33K841.31K2.37M12.45M10.37M9.01M7.88M942.71K435.19K190.19K
R&D as % of Total Revenue206.19%2507.35%164.85%976.86%1577.75%168.56%3927.65%2419.50%302.16%1888.83%4728.09%168.30%39.19%450.77%287.12%309.09%554.23%58.45%107.69%634.56%
Interest Expense30.45K8.54K501.88K0144.81K239.37K000152.21K6.92K45.35K220.17K128.52K69.50K63.01K48.90K21.61K3.55K2.42K
Interest Expense % of Total Revenue0.64%1.75%1.87%0.00%7.33%8.48%0.00%0.00%0.00%377.68%39.96%9.07%3.64%4.65%1.92%2.16%3.44%1.34%0.88%8.08%

Balance Sheet

Currency: CHF2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets46.35M149.37M132.33M88.55M74.28M43.62M21.74M5.88M4.00M2.89M1.68M3.06M42.21M33.03M20.18M22.54M8.28M4.64M10.68M6.37M
Total Liabilities4.07M9.27M13.34M10.97M9.87M9.78M5.44M2.85M1.65M1.23M1.46M1.72M2.97M7.50M5.57M5.61M3.37M3.50M1.00M1.60M
Total Equity42.28M140.11M118.99M77.58M64.41M33.84M16.29M3.03M2.35M1.66M218.59K1.34M39.24M25.52M14.61M16.93M4.91M1.15M9.68M4.77M
Cash40.95M140.04M119.47M76.56M63.80M36.07M15.26M2.91M1.98M2.63M1.42M2.59M41.67M31.54M18.70M20.48M6.96M3.87M3.34M1.64M
Total Debt126.57K------------550.25K567.40K482.01K373.13K344.34K41.99K34.73K
Net Debt-40.82M-140.04M-119.47M-76.56M-63.80M-36.07M-15.26M-2.91M-1.98M-2.63M-1.42M-2.59M-41.67M-30.99M-18.13M-20.00M-6.58M-3.52M-3.30M-1.61M

Cash Flow

Currency: CHF2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-19.56M-33.00M-17.79M-39.38M-31.34M-26.55M-29.45M-15.78M-1.80M-2.63M-2.69M-2.13M1.75M-9.48M-12.18M-14.71M-16.44M-7.99M-5.37M-2.08M
Investing Cash Flow-900.45K-193.49K-2.17M-3.90M-972.80K-758.27K-225.04K256.07K373.45K399.90K-1.51K-697-61.74K-43.25K-59.41K-30.31K2.97K-6.84K4.65M-650.08K
Financing Cash Flow39.61M132.31M-102.29K315.16K19.71M-183.25K8.90M3.18M472.65K2.93M1.49M3.36M37.39M-463.69K46.40K16.40M3.10M5.26M104.92K1.13M
Capital Expenditure357.41K2.73M5.61M4.21M453.02K204.31K330.91K0011.20K11.22K6979.05K28.46K59.41K31.55K5816.84K1.27K0
Free Cash Flow-19.92M-35.73M-23.40M-43.59M-31.79M-26.75M-29.78M-15.78M-1.80M-2.63M-2.71M-2.14M1.74M-9.51M-12.24M-14.74M-16.44M-8.00M-5.37M-2.08M
Dividends Paid--------0000000390.19K307.50K000
FCF to OCF101.83%108.27%131.53%110.69%101.45%100.77%101.12%100.00%100.00%100.00%100.42%100.03%99.48%100.30%100.49%100.21%100.00%100.09%100.02%100.00%
Dividend Paid to FCF--------0.00%0.00%0.00%0.00%0.00%0.00%0.00%-2.65%-1.87%0.00%0.00%0.00%

Earnings

Report DateDec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 11, 2021May 5, 2021Aug 5, 2021Nov 4, 2021Mar 10, 2022May 5, 2022Aug 18, 2022Nov 11, 2022Mar 30, 2023May 11, 2023Aug 10, 2023Nov 13, 2023Jun 6, 2024Nov 11, 2024May 15, 2025Sep 30, 2025Dec 4, 2025Jun 25, 2026Sep 28, 2026Oct 5, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-----0.66-0.79-0.85-0.65-0.52-0.14-0.09-0.05-0.05-0.04-0.03-0.03--0.00----
EPS Actual-1.44-1.13-1.23-1.17-1.13-1.07-1.02-0.77-0.79-0.85-0.85-0.03-0.03-0.06-0.06-0.04-0.04-0.13-0.14-0.07-0.06-0.07-0.06-0.07-0.07-0.07-0.07-0.06-0.060.050.06-0.08-0.08-0.12-0.17-0.14-0.14-0.17-0.12-0.13-0.09-0.53-0.53-0.93-0.72-0.82-0.91-1.19-0.09-1.38-0.27-0.04-4.60-4.0610.17-0.01-0.02-0.01-1.33--
Surprise------------------------------------------19.94%-17.61%15.21%-25.55%-76.95%-779.53%0.00%-2574.42%-420.15%0.00%-14785.44%-13030.42%-------
Timing-----------------------------------------------------Pre-marketPre-market---Pre-marketPre-market-

Key Statistics & Ratios

Market Cap4.38M
Enterprise Value3.39M
Trailing P/E0.00
Forward P/E0.00
Price / Sales40.00
Price / Book1.09
EPS-8.80
Book Value4.07
Revenue (TTM)109.50K
Gross Profit (TTM)-442.22K
EBITDA-2.69M
Profit Margin0.00%
Operating Margin-6238.81%
Return on Equity-122.28%
Return on Assets-23.59%
Shares Outstanding1.27M
Shares Float808.87K
Beta1.96
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 30.00
  • Buy
    1

Ownership Breakdown

Institutions
0.01%
Insiders
0.00%
Retail / Other
99.99%

Top Institutional Holders

  • Morgan Stanley - Brokerage Accounts
    3010.03%
  • Rhumbline Advisers
    720.01%
  • SBI Securities Co Ltd
    10.00%
  • GAMMA Investing LLC
    00.00%
  • UBS Group AG
    00.00%

Stock Splits

  • Oct 23, 20231:20